Madison Vaccines to Present at the 2015 World Vaccine Congress in Washington, D.C., on April 9th
MVI President Richard Lesniewski, PhD, to Speak about Establishing the Role of DNA Vaccines in All Stages of Prostate Cancer
MVI-816 Phase 2 Clinical Trial Now Underway at Three Major Medical Centers
Madison, WI, April 7, 2015 – Madison Vaccines Incorporated (MVI), focused on advancing innovative therapies for prostate cancer, today announced that the company president Richard Lesniewski, PhD, will speak at the 15th annual World Vaccine Congress about “Changing the Conversation in Prostate Cancer, Establishing the Role of DNA Vaccines.”
Prostate cancer is the second leading cause of cancer deaths in men, with more than 230,000 new cases expected in the U.S. based on the National Cancer Institute SEER data base. MVI has two investigational vaccines in three different stages of prostate cancer to provide an alternative to castration therapy in early stage prostate cancer, and to prolong treatment efficacy in later stages. The presentation is scheduled April 9th at 10:00 AM in Washington, D.C.
"How do we change the conversation for prostate cancer patients when their primary therapy has failed, their PSA is rising, and bone metastases are on the way?” asks Dr. Lesniewski. “Currently men can watch and wait, or undergo the rigors of castration therapy. MVI is working to develop an alternative for these men and for men who already have bone metastases and are running out of time."
MVI investigational therapeutics are DNA plasmid vaccines. These are vaccines that can be rapidly and inexpensively manufactured and stored, and do not have to be modified for each individual patient.
MVI’s newest vaccine, MVI-118, could have broad applications with the potential to prolong the duration of disease control that can be achieved with current therapies. It targets the human androgen receptor, the critical biological target that in many cases is responsible for resistance to current therapies.
MVI-816 targets prostatic acid phosphatase (PAP), a well-defined prostate antigen. It will be paired with a PD-1 checkpoint inhibitor in late stage prostate cancer to take full advantage of the latest advances in immunotherapy.
MVI-816 is also in a multi-center Phase 2 clinical trial in early prostate cancer to provide an alternative to hormonal or surgical castration therapy. The Phase 2 clinical trial is taking place at the University of Wisconsin – Madison, and a planned expansion of the trial is now underway at The Johns Hopkins University and University of California San Francisco.
Dr. Lesniewski added, “In my talk I will emphasize our focus on the patient. Recently I heard from a 74 year old (otherwise healthy) veteran whose PSA began rising three years after radiation treatment. He refuses any form of androgen deprivation therapy because he’s concerned about the side effects of castration. Our goal is to change the conversation. We need to provide new options when discussing potential treatments for patients like him.”
Wisconsin-based MVI is developing two plasmid DNA vaccines to treat men with prostate cancer. MVI-816 (pTVG-HP) is designed to activate patients’ immune systems to kill prostate cancer cells after initial treatment but before incurable metastases to the bone. MVI-118 (pTVG-AR) is a second DNA vaccine being developed that targets the human androgen receptor, the critical biological target that in many cases is responsible for resistance to current therapies. MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison. More information is available at www.madisonvaccines.com.